Research Analysts Issue Forecasts for MLYS Q2 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Equities researchers at Lifesci Capital issued their Q2 2025 earnings estimates for Mineralys Therapeutics in a report released on Tuesday, June 17th. Lifesci Capital analyst R. Katkhuda expects that the company will earn ($0.81) per share for the quarter. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($4.23) per share. Lifesci Capital also issued estimates for Mineralys Therapeutics' Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS and FY2025 earnings at ($2.88) EPS.

Several other brokerages have also commented on MLYS. HC Wainwright restated a "buy" rating and issued a $42.00 price objective on shares of Mineralys Therapeutics in a report on Tuesday. Wall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Jefferies Financial Group began coverage on shares of Mineralys Therapeutics in a report on Tuesday, June 10th. They issued a "hold" rating and a $15.00 price objective for the company. Finally, Guggenheim set a $48.00 price objective on Mineralys Therapeutics and gave the company a "buy" rating in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $32.25.

Mineralys Therapeutics Price Performance

Shares of Mineralys Therapeutics stock opened at $13.73 on Thursday. The stock has a market capitalization of $894.92 million, a P/E ratio of -3.68 and a beta of -0.17. The business's 50 day simple moving average is $14.81 and its two-hundred day simple moving average is $12.86. Mineralys Therapeutics has a one year low of $8.24 and a one year high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($1.02) by $0.23.

Insiders Place Their Bets

In other news, insider David Malcom Rodman sold 55,771 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $15.76, for a total value of $878,950.96. Following the sale, the insider now directly owns 116,704 shares of the company's stock, valued at $1,839,255.04. The trade was a 32.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the company's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the sale, the chief financial officer now owns 215,340 shares in the company, valued at $2,597,000.40. The trade was a 4.76% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 104,579 shares of company stock worth $1,534,353. 25.56% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Several large investors have recently modified their holdings of MLYS. Wellington Management Group LLP increased its stake in Mineralys Therapeutics by 43.0% during the 4th quarter. Wellington Management Group LLP now owns 91,529 shares of the company's stock valued at $1,127,000 after purchasing an additional 27,531 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Mineralys Therapeutics in the fourth quarter worth $202,000. Proficio Capital Partners LLC bought a new position in Mineralys Therapeutics during the 4th quarter valued at about $285,000. BNP Paribas Financial Markets purchased a new stake in Mineralys Therapeutics in the fourth quarter worth approximately $48,000. Finally, Charles Schwab Investment Management Inc. grew its position in Mineralys Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company's stock worth $2,645,000 after purchasing an additional 1,307 shares during the period. Hedge funds and other institutional investors own 84.46% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.